TY - JOUR T1 - Prognostic relevance of histological subtypes in lung cancer - Survival in frequent and rare entities JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P4524 AU - Anne Gastmeier AU - Torsten Blum AU - Jens Kollmeier AU - Sergej Griff AU - Wim Ammenwerth AU - Sandra Delis AU - Wiebke Nehls AU - Tarek Sabha AU - Thiel Sebastian AU - Nicolas Schönfeld AU - Torsten T. Bauer Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P4524.abstract N2 - Introduction: During the last years molecular alterations as well as targeted therapies have gained the focus of interest in lung cancer care. However, knowledge about rare lung cancer entities remains limited.Aims: This study evaluated the stage-dependent significance of histology on survival in lung cancer patients.Methods: All patients with a primary diagnosis of lung cancer between 01/2000 and 12/2011 were prospectively recorded within our tumour registry and retrospectively evaluated with regard to histology, stage and survival.Results: A total of 7,351 patients were identified: 4,690 men (63.8%) and 2,661 women (36.2%). Mean age was 65.2 yrs. Stage I, II, III, IV, and unknown was present in 16.7%, 8.4%, 32.6%, 39.6%, and 2.7%, respectively. Histological subtyping revealed: adeno 39.3%, squamous 28.1%, adenosquamous 0.4%, large cell with (1.8%) and w/o (2.4%) neuroendocrine diff., sarcomatoid 0.8%, salivary gland 0.1%%, NSCLC NOS 5.1%, SCLC 13.4%, combined SCLC 0.9%, neuroendocrine NOS 1.1%, undiff. carcinoma 6.7%. Stage-dependent overall survival showed a high variance for the different histological subtypes. For example, sarcomatoid carcinoma in stage IV had a poorer OS compared to all other entities (p=0.003).Conclusion: Stratifying lung cancer by histology demonstrated poorer OS for rare subgroups. Insufficient evidence and absent treatment standards in these entities might contribute to these findings. ER -